A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

Ernie Hudson is tempting his fans with a sexy new partnership.   The “Ghostbusters” actor is joining forces with ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...